Trending...
- California: Governor Newsom announces appointments 9.10.25 - 391
- John Thomas calls for unity and prayer after tragic loss - 357
- Ayurveda, Ayurvedic medical Science and Ayurvedic Therapies, Dr.Abhay Kumar Pati - 355
PALO ALTO, Calif., May 20, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that management will present at the following upcoming virtual investor conferences:
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
- Jefferies Virtual Healthcare Conference on Thursday, June 3 at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time)
- Goldman Sachs 42nd Annual Global Healthcare Conference on Tuesday, June 8 at 1:40 p.m. Pacific Time (4:40 p.m. Eastern Time)
A live webcast of both presentations will be available on the "Events and Presentations" section of Kodiak's website at http://ir.kodiak.com/ and will remain available for replay for a limited time following the events.
About Kodiak Sciences Inc.
Kodiak (Nasdaq: KOD) is a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform™ uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, the leading cause of blindness in elderly patients in the developed world, and diabetic eye diseases, the leading cause of blindness in working-age patients in the developed world. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit www.kodiak.com.
More on The Californer
- Stringify AI Launches Complaint Classifier to Automate Enterprise Support Triage
- Hazel-E Hosts Pop-Up Gifting Suite on Melrose
- iPOP Administration & Talent Fund Clean Water Project in Africa, Through the Thirst Project
- California: Governor Newsom announces appointments 9.16.25
- Hollywood Veterans and Rising Stars Join Forces on "HOA" A Vertical Sitcom Designed for Social Media
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.
SOURCE Kodiak Sciences Inc.
Related Links
http://www.kodiak.com
Filed Under: Business
0 Comments
Latest on The Californer
- 'The Lonely Diners Club' Goes Into Pre-Production
- Tour Napa Like a Local: Vines of Napa Valley Wine Passport AKA Vine Pass Unlocks Hidden Gems
- Changzhou Huifeng Vehicle Parts Factory Continues Participation 2025 AAPEX Show at Las Vegas
- Dental Surgical Center Accepts Sedation Patients with Medicaid for MD, WV, PA and DC
- Attn: Business: Looking for ways to Increase your Sales and Profit? Start using this Marketing Math
- END WELL 2025 SUMMIT BRINGS "RADICAL BRAVERY" TO LOS ANGELES, FEATURING EMMA HEMING WILLIS AND YVETTE NICOLE BROWN AMONG LEADING VOICES IN END-OF-LIFE TRANSFORMATION
- Long Beach: City to Host Community Demo Day to Showcase Neighborhood Technology Solutions
- Sloan's Lake Dental Launches New Website to Enhance Patient Experience and Access to Modern Dental Care
- Upcoming River City Ball & Brawl Bundle Includes Kunio-kun's Basketball & Tournament Fighting
- Only 3 Weeks Left till the Start of the OpenSSL Conference 2025
- Sanguine Expands Oncology Biospecimen Offerings Through Strategic Clinic Partnerships
- ENTOUCH Completes $50 million Funding Round
- Teaming Agreement with Emtel Energy USA to Advance Thin-Film PV Energy Storage Capabilities; NASA agreements for Solar Space Tech; Ascent Solar $ASTI
- Nebuvex Acknowledges Platform "Too Secure" for Anonymous Traders; Institutional Investors Disagree
- From Tokyo to Berlin: FreeTo.Chat Unites Cultures with the World's First Confession VRX — EmojiStream™
- McKenzi Brooke Set to Electrify the Super Girl Surf Festival in Oceanside, California
- AZETHIO Launches Multi-Million Dollar User Protection Initiative Following Unprecedented Platform Growth
- Matecrypt Observes South American Cryptocurrency Adoption Surge Amid Economic Shifts
- Assent Uncovers Over 695 Unique PFAS Across Global Supply Chains as Regulations Increase
- Ascend in Motion Expands Flat-Rate Transfers from LAX to San Diego